{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:03:49Z","timestamp":1783771429623,"version":"3.55.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Psychedelic Medicine"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have gained interest as potentially efficacious options, known to generate unique psychotherapeutic experiences. The present secondary analysis examines the acute subjective experiences\u2014both quantitatively and qualitatively\u2014of clinical trial participants with AUD who received intravenous (IV) ketamine therapy in the hospital setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Among a subset of inpatient clinical trial participants with AUD who received IV ketamine therapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200912), acceptability and tolerability were assessed. Next, a brief directed content analysis was performed, utilizing textual data transcribed immediately after ketamine infusion. Six preselected themes from the literature were chosen to apply to our text.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among this sample, IV ketamine therapy appeared well tolerated and highly acceptable (mean 9.5 on 0\u201310 Likert scale). The mean Clinician-Administered Dissociative States Scale (CADSS) score was 21.7 (out of max 92). It seemed to occasion experiences that were largely positive, transporting, visual, and meaningful. The most frequently assigned themes in our data set were \u201cMeaningful, spiritual, and mystical experiences,\u201d \u201cPositive affect,\u201d and \u201cInherent contradictions of the acute experience.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Prior themes derived from two theory-generating publications applied widely to our participants' reported experiences. The hospital setting itself did not appear to be a barrier in facilitating these experiences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/psymed.2023.0066","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T14:05:06Z","timestamp":1709820306000},"page":"116-126","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute Subjective Experiences of Intravenous Ketamine Therapy Among Medically Hospitalized Patients with Alcohol Use Disorder"],"prefix":"10.1177","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-1608","authenticated-orcid":false,"given":"Dale","family":"Terasaki","sequence":"first","affiliation":[{"name":"Department of Behavioral Health, Denver Health &amp; Hospital Authority, Denver, Colorado, USA."},{"name":"Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Table 5.6A\u2014Alcohol Use Disorder in Past Year: Among People Aged 12 or Older; by Age Group and Demographic Characteristics Numbers in Thousands 2021. Center for Behavioral Health Statistics and Quality. 2021 National Survey on Drug Use and Health; 2021. Available from: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39441\/NSDUHDetailedTabs2021\/NSDUHDetailedTabs2021\/NSDUHDetTabsSect5pe2021.htm#tab5.6a [Last accessed May3 2023]."},{"key":"e_1_3_3_3_2","unstructured":"American Society of Addiction Medicine (ASAM) Board of Directors. Definition of Addiction. American Society of Addiction Medicine (ASAM); 2019:2. Available from: https:\/\/www.asam.org\/docs\/default-source\/quality-science\/asam's-2019-definition-of-addiction-(1).pdf?sfvrsn=b8b64fc2_2 [Last accessed: May3 2023]."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4308"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0249"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000079"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.36518\/2689-0216.1243"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2234"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.21.1.108"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-017-9759-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-11-200812020-00004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kax053"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v38.1.11"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30078-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0011"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874473708666150107121331"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144"},{"key":"e_1_3_3_18_2","unstructured":"U.S. Food and Drug Administration. FDA News Release | FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available Only at a Certified Doctor's Office or Clinic. FDA; 2019. Available from: www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified [Last accessed: January8 2020]."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109606"},{"issue":"5","key":"e_1_3_3_20_2","article-title":"Ketamine treatment for alcohol use disorder: A systematic review","volume":"15","author":"Kelson M","unstructured":"Kelson M, , Burnett JM, , Matthews A, et al. Ketamine treatment for alcohol use disorder: A systematic review. Cureus, 15(5):e38498; doi: 10.7759\/cureus.38498","journal-title":"Cureus"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13162-w"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19070684"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.21030277"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.695335"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.02.017"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06324-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.017"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.12.023"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42141-5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-023-00140-x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120970879"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1037\/qup0000196"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00345-y"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.05.007"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05251-9"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2023.2225977"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12060782"},{"key":"e_1_3_3_38_2","unstructured":"Cooper L. A Study Investigating the Relaxation Effects of the Music Track Weightless by Marconi Union in Consultation with Lyz Cooper. Sussex Innovation Centre University of Sussex 2011; p. 8. Available from: https:\/\/www.britishacademyofsoundtherapy.com\/wp-content\/uploads\/2019\/10\/Mindlab-Report-Weightless-Radox-Spa.pdf [Last accessed: February1 2020]."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024465317902"},{"key":"e_1_3_3_42_2","unstructured":"Mayring P. Qualitative content analysis. Forum: Qualitative Social Research 2000; 1(2). Available from: https:\/\/www.qualitative-research.net\/index.php\/fqs\/article\/view\/1089\/2385 [Last accessed: November6 2023]."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305276687"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2307\/1384454"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.copsyc.2015.03.001"},{"issue":"1","key":"e_1_3_3_46_2","first-page":"25","article-title":"Kindling in alcohol withdrawal","volume":"22","author":"Becker HC","year":"1998","unstructured":"Becker HC. Kindling in alcohol withdrawal. Alcohol Health Res World, 1998; 22(1):25\u201333.","journal-title":"Alcohol Health Res World"},{"key":"e_1_3_3_47_2","unstructured":"Rahman A Paul M. Delirium Tremens. StatPearls Publishing; 2023. Available from: www.ncbi.nlm.nih.gov\/books\/NBK482134 [Last accessed: December24 2023]."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.01.002"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12671"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108708"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300252"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.161.10.1776"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-4-25"}],"container-title":["Psychedelic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/psymed.2023.0066","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:27:22Z","timestamp":1777685242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/psymed.2023.0066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.1089\/psymed.2023.0066"],"URL":"https:\/\/doi.org\/10.1089\/psymed.2023.0066","relation":{},"ISSN":["2831-4425","2831-4433"],"issn-type":[{"value":"2831-4425","type":"print"},{"value":"2831-4433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}